[Skip to Content]
[Skip to Content Landing]
April 17, 1981

Adjuvant Chemotherapy for Breast Cancer

Author Affiliations

The University of Arizona Health Sciences Center Tucson

JAMA. 1981;245(15):1527-1528. doi:10.1001/jama.1981.03310400013013

To the Editor.—  How can there be a "consensus" when all relevant information is not presented?I wish to clarify several points attributed to me in the recent MEDICAL NEWS article (1980;244:1079) on the National Cancer Institute Consensus Conference on Adjuvant Chemotherapy of Breast Cancer.1Regarding the use of adjuvant chemotherapy for node-negative (stage I) cases, I reported on the preliminary results of a pilot study wherein two patients have relapsed out of 52 treated with adjuvant chemotherapy. At no time during the conference did I advocate the routine use of adjuvant chemotherapy in this setting—I repeatedly stated that this is an on-going research program and that the preliminary results should be judged on their own merits. Since many larger groups of investigators (eg, cooperative groups) are now just initiating controlled trials for stage I cases, the data we presented from our pilot program might provide some background and